|
Re: RESVERLOGIX ANNOUNCES VOTING RESULTS FROM THE 2022 MEETING OF SHAREHOLDERS
|
3
|
Resverlogix Corp.
|
Jun 22, 2022 03:25PM
|
|
Re: RESVERLOGIX ANNOUNCES VOTING RESULTS FROM THE 2022 MEETING OF SHAREHOLDERS
|
7
|
Resverlogix Corp.
|
Jun 22, 2022 04:31PM
|
|
Re: Resverlogix Announces US$30 Million Loan Commitment Letter .
|
6
|
Resverlogix Corp.
|
Apr 11, 2018 08:34AM
|
|
Re: Resverlogix Announces Two New Publications on Apabetalone in Kidney Disease
|
8
|
Resverlogix Corp.
|
Mar 28, 2018 08:00AM
|
|
Re: Resverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics
|
3
|
Resverlogix Corp.
|
Aug 04, 2020 05:03PM
|
|
Re: RESVERLOGIX ANNOUNCES PUBLICATION OF KEY APABETALONE STUDY BETONMACE IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
|
2
|
Resverlogix Corp.
|
Mar 30, 2020 12:15PM
|
|
Re: RESVERLOGIX ANNOUNCES PUBLICATION OF KEY APABETALONE STUDY BETONMACE IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
|
3
|
Resverlogix Corp.
|
Mar 30, 2020 07:20PM
|
|
Re: RESVERLOGIX ANNOUNCES PUBLICATION OF KEY APABETALONE STUDY BETONMACE IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
|
1
|
Resverlogix Corp.
|
Mar 31, 2020 05:43PM
|
|
Re: Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA
|
3
|
Resverlogix Corp.
|
Jan 08, 2017 09:44AM
|
|
Re: Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients
|
2
|
Resverlogix Corp.
|
Jun 12, 2023 06:15PM
|
|
Re: Resverlogix Announces Extension of Maturity Date of Loan and Expression of Interest Regarding Strategic Transaction
|
4
|
Resverlogix Corp.
|
Aug 28, 2017 10:36AM
|
|
Re: Resverlogix Announces Corporate Update Webcast... Sarah..
|
6
|
Resverlogix Corp.
|
Jun 09, 2016 04:07PM
|
|
Re: Resverlogix Announces Corporate Update Conference Call...
|
3
|
Resverlogix Corp.
|
Jun 06, 2020 09:30AM
|
|
Re: Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment
|
7
|
Resverlogix Corp.
|
Jan 18, 2022 08:18AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
8
|
Resverlogix Corp.
|
Dec 22, 2020 08:47AM
|
|
Re: Resverlogix and Zenith AGMs
|
5
|
Resverlogix Corp.
|
Aug 23, 2016 11:40AM
|
|
Re: Resverlogix and Zenith AGMs
|
1
|
Resverlogix Corp.
|
Aug 23, 2016 09:48AM
|
|
Re: Resverlogix & Zenith, hmmm...
|
4
|
Resverlogix Corp.
|
May 15, 2015 08:04PM
|
|
Re: Resverlogix & Zenith, hmmm...
|
3
|
Resverlogix Corp.
|
May 15, 2015 09:39PM
|
|
Re: Reports of Exempt Distribution
|
2
|
Zenith Epigenetics
|
Feb 24, 2023 11:27AM
|
